|
 | Edward W. GereckeShareholder
Carlton Fields, P.A.
4221 West Boy Scout Boulevard, Suite 1000
Tampa, Florida
33607-5736
(Hillsborough Co.)
Mailing Address: P.O. Box 3239, Tampa, FL, 33601-3239
Telephone: 813-229-4306
Fax: 813-229-4133
http://www.carltonfields.com
|
Profile Visibility  | | #452 in weekly profile views out of 4,191 lawyers in Tampa, Florida | | #60,152 in weekly profile views out of 968,464 total lawyers Overall |
|
|
| |
| Practice Areas | Drug and Medical Device Defense; Products Liability Defense; Personal Injury Defense | | | Education | Indiana University, J.D., with honors, 1981, Purdue University, B.S., with distinction, 1978 | | | Admitted | 1981, Florida; U.S. District Court, Northern, Middle and Southern Districts of Florida; U.S. Court of Appeals, Eleventh Circuit; U.S. Supreme Court | |
| Memberships | American Bar Association (Product Liability Committee, Litigation Section); American Board of Trial Advocates (Treasurer, 2008); International Association of Defense Counsel; Federation of Defense & Corporate Counsel; Florida Defense Lawyers Association; Defense Research Institute (Member: Drug & Medical Device Committee; Steering Committee); Product Liability Advisory Council. | | | Born | St. Catharines, Ontario, Canada, 1956 | | | Biography | Author: "Section 6(c) of the Third Restatement: Design Defects in Prescription Medical Products," DRI's For The Defense, April 2006; "Demanding Reliability From Experts Under Florida Law," The Florida Bar Journal, July/August 2001; "State-by-State Summary of the Law on FDCA - Related Cases Of Action (Florida Section)," ABA, 2001; "Halting Regulation Through Litigation," The National Law Journal, October 9, 2000; "State-by-State Summary of the Law on Liability for Off-Label Use of Drugs and Medical Devices," ABA, August 1999; "Market Share Theory: Limited Logic Meets Some Logical Limits," For The Defense, September 1998; "Unavoidably Unsafe Drugs, The Future of Comment K," For The Defense, December 1992. Co-Author, "The Restatement (Third) of Torts and its Projected Impact upon Manufacturers of Prescription Drugs and Medical Devices," DRI Drug & Medical Device Committee, 1998. Editor, "State-by-State Summary of Ex Parte Contacts With Treating Physicians," ABA, January 1995.(Board Certified Civil Trial Advocacy Specialist by the National Board of Trial Advocacy) | | | Reported Cases | Sharp v. Wyeth, 2006 WL 515532 (Fla. Cir Ct. 2006); Marzullo v. Crosman Corp., 289 F.Supp 2d 1337 (M.D. Fla 2003); Marking v. Novartis, 2001 WL 32255405 (S.D. Fla 2002); Savage v. Danek Medical, Inc., 31 F. Supp. 2d 980 (M.D. Fla. 1999), aff'd 202, F.3d 288 (11th Cir. 1999); King v. Cutter Laboratories, 714 So. 2d 351 (Fla. 1998); Walls v. Armour Pharmaceutical Company, 53 F.3d 1184 (11th Cir. 1995); Reynard v. NEC Corp., 887 F.Supp. 1500 (M.D. Fla. 1995); Jones v. Upjohn Co., 661 So.2d 356 (Fla. 2d DCA 1995); Chikovsky v. Ortho Pharmaceutical Company, 832 F.Supp. 341 (S.D. Fla. 1993); Mitchell v. VLI Corp., 786 F. Supp. 966 (M.D.Fla 1992); Adams v. G.D. Searle & Co., 576 So. 2d 728 (Fla. 2d DCA 1991), rev. den., 589 So. 2d 290 (1991). | | | ISLN | 907136949 | |
|
|
RSS | Blog | Advertising Opportunities | Site Map | Contact Us
